# US 2010/0166769 A1 · High-yield Transgenic Mammalian Expression System for Generating Virus-like Particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166769 A1
- Document ID: US20100166769A1
- Status: Published application
- Kind: A1
- Application number: 12/704,928
- Filed: 2010-02-12
- Published: 2010-07-01
- Earliest claimed: 2006-09-05
- Assignees: Academia Sinica
- Inventors: Pei-Wen Hsiao; Chia- Ying Wu; Yi-Chun Yeh
- Web page: https://patentgrep.com/patent/US20100166769A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61P 31/16: for influenza or rhinoviruses
- C07K 14/005: from viruses
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- G01N 33/56983: {Viruses}
- A61K 2039/5258: {Virus-like particles}
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16123: Virus like particles [VLP]
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20023: Virus like particles [VLP]
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2830/006: tet repressible
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.

## Claims

### Claim 1

A method of preparing an influenza virus-like particle (VLP), the method comprising:
obtaining a founder Vero cell stably transfected with a sequence encoding an influenza M1 and a sequence encoding an influenza M2;
constructing at least one recombinant DNA molecule comprising a sequence encoding an influenza hemagglutinin (HA) and a sequence encoding an influenza neuraminidase (NA);
introducing the at least one recombinant DNA molecule into the founder Vero cell to obtain a co-expression Vero cell stably transfected with the sequences encoding the influenza M1 and the influenza M2, and further transfected with the sequences encoding the influenza HA and the influenza NA, wherein the expressions of the influenza M1, M2, HA and NA proteins in the co-expression Vero cell are controlled by one or more inducible expression systems;
culturing the co-expression Vero cell under conditions to allow expressions of the influenza M1, the influenza M2, the influenza HA and the influenza NA, and assembly of the VLP comprising the influenza M1, the influenza M2, the influenza HA and the influenza NA; and
isolating the VLP from the culture supernatant of the co-expression Vero cell.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the founder Vero cell is derived from Vero E6 cell.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the influenza HA and the influenza NA are derived from one or more potentially pandemic or seasonal influenza virus strains.

### Claim 4 (depends on 1)

The method according to claim 1, wherein
the at least one recombinant DNA molecule further comprises a sequence encoding a second influenza HA and a sequence encoding a second influenza NA, wherein the influenza HA and the second influenza HA are derived from different influenza virus strains, and the influenza NA and the second influenza NA are derived from different influenza virus strains;
the co-expression Vero cell is further transfected with the sequences encoding the second influenza HA and the second influenza NA; and
the culturing step allows expressions of the influenza M1, the influenza M2, the influenza HA, the influenza NA, the second influenza HA and the second influenza NA, and assembly of the VLP comprising the influenza M1, the influenza M2, at least one of the influenza HA and the second influenza HA, and at least one of the influenza NA and the second influenza NA.

### Claim 5

A method of preparing an influenza virus-like particle (VLP), the method comprising:
obtaining a co-expression Vero cell stably transfected with a sequence encoding an influenza M1 and a sequence encoding an influenza M2, and further transfected with a sequence encoding an influenza hemagglutinin (HA) and a sequence encoding an influenza neuraminidase (NA), wherein the expressions of the influenza M1, M2, HA and NA proteins in the co-expression Vero cell are controlled by one or more inducible expression systems; and
culturing the co-expression Vero cell under conditions to allow expressions of the influenza M1, the influenza M2, the influenza HA and the influenza NA, and assembly of the VLP comprising the influenza M1, the influenza M2, the influenza HA and the influenza NA; and
isolating the VLP from the culture supernatant of the co-expression Vero cell

### Claim 6

An influenza virus-like particle (VLP), comprising:
an influenza M1, an influenza M2, an influenza hemagglutinin (HA) and an influenza neuraminidase (NA), wherein the influenza proteins are recombinantly expressed from a Vero cell; and
at least one cellular protein of the Vero cell.

### Claim 7 (depends on 6)

The influenza VLP of claim 6, wherein the Vero cell is Vero E6 cell.

### Claim 8 (depends on 6)

The influenza VLP of claim 6, wherein the influenza HA and the influenza NA are derived from one or more potentially pandemic or seasonal influenza virus strains.

### Claim 9 (depends on 6)

The influenza VLP of claim 6, further comprising a second influenza HA and a second influenza NA, wherein the influenza HA and the second influenza HA are derived from different influenza virus strains, and the influenza NA and the second influenza NA are derived from different influenza virus strains.

### Claim 10 (depends on 6)

The influenza VLP of claim 6, comprising M1 and M2 of influenza A/Taiwan/083/2006, and H3 and N2 of influenza A/Taiwan/083/2006, or H5 and N1 of influenza A/Hanoi/30408/2005(H5N1), respectively.

### Claim 11 (depends on 6)

The influenza VLP of claim 6, wherein the at least one cellular protein is selected from the group consisting of clathrin heavy chain 1, spectrin beta, plexin B2, CD109 homolog, prostaglandin F2 receptor negative regulator, Na+/K+-ATPase alpha 1, tumor rejection antigen (gp96) 1 and flotillin I.

### Claim 12 (depends on 6)

An immunogenic composition comprising an immunogenic effective amount of the influenza VLP of claim 6 and a pharmaceutically acceptable excipient.

### Claim 13 (depends on 12)

The immunogenic composition of claim 12 further comprising an adjuvant.

### Claim 14 (depends on 12)

A method of inducing immunity against an influenza virus in a subject, the method comprising administering to the subject the immunogenic composition of claim 12, wherein the influenza VLP comprises the HA and the NA derived from the influenza virus.

### Claim 15 (depends on 6)

A method of providing protection against an influenza virus in a subject, the method comprising vaccinating the subject with a vaccine comprising the influenza VLP of claim 6, wherein the influenza VLP comprises the HA and the NA derived from the influenza virus.

### Claim 16 (depends on 6)

A method of diagnosing infection by an influenza virus in a subject, the method comprising:
obtaining a biological sample from the subject;
contacting the biological sample with the influenza VLP of claim 6, wherein the influenza VLP comprises the HA and the NA derived from the influenza virus; and
measuring in the biological sample the amount of an antibody that forms an antibody-antigen complex with the influenza VLP,
wherein a higher than a threshold amount of the antibody indicates that the subject has ever been infected by the influenza virus or vaccinated by a similar strain of virus.

### Claim 17 (depends on 6)

An antibody against the influenza VLP of claim 6.

### Claim 18 (depends on 17)

A method of preparing the antibody of claim 17, comprising:
administering the VLP to a vertebrate; and
harvesting the antibody against the VLP from the blood of the vertebrate.

### Claim 19 (depends on 17)

A method of treating infection by an influenza virus in a subject, the method comprising administering to the subject the antibody of claim 17, wherein the influenza VLP comprises the HA and the NA derived from the influenza virus.

### Claim 20 (depends on 17)

A method for detecting infection by an influenza virus in a subject, the method comprising:
obtaining a biological sample from the subject;
contacting the biological sample with the antibody of claim 17; and
detecting in the biological sample an antigen that forms an antibody-antigen complex with the antibody,
wherein the presence of the antigen in the biological sample indicates that the subject is infected by the influenza virus.

### Claim 21

A founder Vero cell being a Vero cell stably transfected with a sequence encoding an influenza M1 and a sequence encoding an influenza M2, wherein the expressions of the influenza M1 and M2 proteins in the founder Vero cell are controlled by an inducible expression system.

### Claim 22 (depends on 21)

The founder Vero cell of claim 21, wherein the Vero cell is Vero E6 cell.

### Claim 23 (depends on 21)

The founder Vero cell of claim 21 further transfected with a sequence encoding an influenza protein different from the influenza M1 and M2 proteins.

### Claim 24 (depends on 23)

The founder Vero cell of claim 23 being a co-expression Vero cell stably transfected with the sequence encoding the influenza M1 and the sequence encoding the influenza M2, and further transfected with a sequence encoding an influenza hemagglutinin (HA) and a sequence encoding an influenza neuraminidase (NA), wherein the expressions of the influenza M1, M2, HA and NA proteins in the co-expression Vero cell are controlled by one or more inducible expression systems.

### Claim 25

A method of obtaining a founder Vero cell, the method comprising:
introducing into a Vero cell a sequence encoding an influenza M1 and a sequence encoding an influenza M2; and
obtaining the founder Vero cell stably transfected with the sequence encoding the influenza M1 and the sequence encoding the influenza M2,
wherein the expressions of the influenza M1 and M2 proteins in the founder Vero cell are controlled by an inducible expression system.

### Claim 26 (depends on 25)

The method of claim 25, further comprising:
introducing into the founder Vero cell a sequence encoding an influenza hemagglutinin (HA) and a sequence encoding an influenza neuraminidase (NA); and
obtaining a co-expression Vero cell stably transfected with the sequence encoding the influenza M1 and the sequence encoding the influenza M2, and further transfected with the sequence encoding the influenza HA and the sequence encoding the influenza NA,
wherein the expressions of the influenza M1, M2, HA and NA proteins in the co-expression Vero cell are controlled by one or more inducible expression systems.
